Earnings Beat: Medistim ASA Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Medistim ASA (OB:MEDI) investors will be delighted, with the company turning in some strong numbers with its latest results. Medistim delivered a significant beat to revenue and earnings per share (EPS) expectations, hitting kr202m-12% above indicated-andkr2.85-28% above forecasts- respectively The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
Taking into account the latest results, the most recent consensus for Medistim from twin analysts is for revenues of kr798.5m in 2026. If met, it would imply a reasonable 6.1% increase on its revenue over the past 12 months. In the lead-up to this report, the analysts had been modelling revenues of kr768.0m and earnings per share (EPS) of kr9.20 in 2026. What's really interesting is that while the consensus made a small lift in revenue estimates, it no longer provides an earnings per share estimate. This suggests that revenues are now the focus of the business after this latest result.
Check out our latest analysis for Medistim
The average price target rose 5.6% to kr333, with the analysts clearly having become more optimistic about Medistim'sprospects following these results.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The period to the end of 2026 brings more of the same, according to the analysts, with revenue forecast to display 12% growth on an annualised basis. That is in line with its 12% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 7.3% per year. So it's pretty clear that Medistim is forecast to grow substantially faster than its industry.
The Bottom Line
The highlight for us was that the analysts increased their revenue forecasts for Medistim next year. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.
We have estimates for Medistim from its twin analysts out to 2028, and you can see them free on our platform here.
Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.